RT Journal Article
SR Electronic
T1 Inflammatory markers in Covid-19 Patients: a systematic review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.29.20084863
DO 10.1101/2020.04.29.20084863
A1 Vaseghi, Golnaz
A1 Mansourian, Marjan
A1 Karimi, Raheleh
A1 Heshmat-Ghahdarijani, Kiyan
A1 Rouhi, Paria
A1 Shariati, Mahfam
A1 Javanmard, Shaghayegh Haghjoo
YR 2020
UL http://medrxiv.org/content/early/2020/05/02/2020.04.29.20084863.abstract
AB Introduction Diagnosis of COVID-19 is based on clinical manifestation, history of exposure, positive findings on chest CT and laboratory tests. It has been shown that inflammation plays a role in pathogenesis of COVID-19.Method We used the necessary transformations to convert the median and IQR to mean and SD Random-effect model using Der Simonian, and Laird methods was used if heterogeneity between studies was significant, the homogeneity among studies was assessed with I2 Statistic, values above 50%, and for the chi-square test, P-values <0.1 was supposed statistically significantResults Twelve studies were included in the analysis that all of which were conducted in China in the year 2020. The result of combining 12 articles with 772 participants showed that the pooled estimate of the mean of lymphocyte with 95% CI was (Mean: 1.01; 95% CI (0.76-1.26); p-value<0.001). About WBC the pooled result of 9 studies with 402 participants was (Mean: 5.11; 95% CI (3.90-6.32); p-value<0.001) Also the pooled mean estimate of 9 studies with 513 patients for the ratio of Neutrophil/lymphocyte was (Mean: 3.62; 95% CI (1.48-5.77); p-value=0.001). The pooled mean from the combination of 7 studies with 521 patients on CRP was (Mean: 28.75; 95% CI (8.04-49.46).Conclusion Inflammatory Markers increase in patients with Covid-19, which can be a good indicator to find patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors had no support from any person or institution.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data is available in the full text article